Associated Papers
Integrative Computational Analysis of TP53 Exon 5-6 Mutations in Oral Cavity, Prostate, and Breast Cancers in a Senegalese Population.
Mbaye M et al.
Genes, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
The TP53 tumor suppressor gene: From molecular biology to clinical investigations.
Baliakas P et al.
Journal of Internal Medicine, 2025
TP53: the unluckiest of genes?
Joerger AC et al.
Cell Death and Differentiation, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
Mis-splicing drives loss of function of p53E224D point mutation.
Lock IC et al.
Plos One, 2025
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.
Ahmadi SE et al.
Biomarker Research, 2024
Navigating the complexity of p53-DNA binding: implications for cancer therapy.
Thayer KM et al.
Biophysical Reviews, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
Mis-splicing Drives Loss of Function of p53E224D Point Mutation.
Lock IC et al.
Biorxiv : the Preprint Server for Biology, 2023
Transcription-independent functions of p53 in DNA repair pathway selection.
Wang YH et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology, 2023
The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots.
Lazarian G et al.
Human Mutation, 2023
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X et al.
Cell Death & Disease, 2022
Identification of mutant p53-specific proteins interaction network using TurboID-based proximity labeling.
Hu S et al.
Biochemical and Biophysical Research Communications, 2022
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.
Li Z et al.
Npj Breast Cancer, 2022
Should mutant TP53 be targeted for cancer therapy?
Wang Z et al.
Cell Death and Differentiation, 2022
Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity.
Wang YH et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blombery P et al.
Blood, 2022
p53 partial loss-of-function mutations sensitize to chemotherapy.
Klimovich B et al.
Oncogene, 2022
Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Brown K et al.
Frontiers in Oncology, 2022
TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.
Noor H et al.
Cancers, 2021
Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study.
Huang CS et al.
Journal of Personalized Medicine, 2021
Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy.
Timofeev O et al.
Cancers, 2021
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.
Doffe F et al.
Cell Death and Differentiation, 2021
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Maroni G et al.
Communications Biology, 2021
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y et al.
Carcinogenesis, 2020
KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation.
Shao N et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2020
Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.
Klimovich B et al.
Cell Cycle (georgetown, Tex.), 2020
Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
Boyarskikh UA et al.
Frontiers in Oncology, 2020
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Monti P et al.
Frontiers in Oncology, 2020
Mutant p53 as a Regulator and Target of Autophagy.
Shi Y et al.
Frontiers in Oncology, 2020
How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.
Ho T et al.
International Journal of Molecular Sciences, 2019
Rapid generation and selection of Cas9-engineering TRP53 R172P mice that do not have off-target effects.
Zheng G et al.
Bmc Biotechnology, 2019
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.
Timofeev O et al.
The Embo Journal, 2019